Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 429-438

  Annabi, Borhane ^a   Bouzeghrane, Mounia ^b   Currie, Jean Christophe ^a   Dulude, Hélène ^c   Daigneault, Luc ^c   Garde, Seema ^c   Rabbani, Shafaat A ^d   Panchal, Chandra ^c   Wu, Jinzi J ^c   Béliveau, Richard ^a,b  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Extracellular signal regulated protein kinase; HuR; Laminin receptor; Metalloproteinase 9; Metastasis; Prostate cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; BIOTIN; FLUORESCEIN ISOTHIOCYANATE; GELATIN; GELATINASE B; HUR PROTEIN; LAMININ; LAMININ RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PCK 3145; PEPTIDE DERIVATIVE; PROSTATE SECRETORY PROTEIN 94 [31-45]; PROSTATIC SECRETORY PROTEIN; RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL LYSATE; CELL SURFACE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA STABILITY; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

ANTIGENS, SURFACE; BONE NEOPLASMS; CELL LINE, TUMOR; FLAVONOIDS; HUMANS; LAMININ; MALE; MATRIX METALLOPROTEINASE 9; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, LAMININ; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 33745010127     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000203388.68034.06     Document Type: Article

References (28)

1. Yang JP, Finkelman MA, Clarke MW. Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP. J Urol 1998; 160:2240-2244.
2. Abrahamsson PA, Lilja H. Three predominant prostatic proteins. Andrologia 1990; 22:122-131.
3. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, Saito Y. Prognostic significance of β-microseminoprotein mRNA expression in prostate cancer. Prostate 1999; 38:278-284.
4. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003; 63:2072-2078.
5. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 2004; 64:5370-5377.
6. Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, et al. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer 2005; 4:91-99.
7. Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, et al. A prostate secretory protein94-derived synthetic peptide PCK3145 antagonizes VEGF signaling in endothelial cells: implication in tumor angiogenesis. Int J Cancer 2006; in press.
8. Annabi B, Bouzeghrane M, Currie JC, Ruiz MT, Wisniewski J, Garde S, et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implication in tumor metastasis. Clin Exp Metastasis 2005; 22:429-439.
9. Silver FH, Trelstad RL. Type I collagen in solution. Structure and properties of fibril fragments. J Biol Chem 1980; 255:9427-9433.
10. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 1996; 271:8144-8151.
11. Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, Béliveau R. Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 1999; 45:1432-1440.
12. Rigot V, Lehmann M, Andre F, Daemi N, Marvaldi J, Luis J. Integrin ligation and PKC activation are required for migration of colon carcinoma cells. J Cell Sci 1998; 111:3119-3127.
13. Plant NJ, Ogg M, Crowder M, Gibson GG. Control and statistical analysis of in vitro reporter gene assays. Anal Biochem 2000; 278:170-174.
14. Wang JM, Hishinuma A, Oppenheim JJ, Matsushima K. Studies of binding and internalization of human recombinant monocyte chemotactic and activating factor (MCAF) by monocytic cells. Cytokine 1993; 5:264-275.
15. Annabi B, Thibeault S, Moumdjian R, Béliveau R. Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem 2004; 279:21888-21896.
16. Annabi B, Lachambre MP, Bousquet-gagnon N, Pagé M, Gingras D, Béliveau R. Inhibition of MMP-2 secretion and MT1-MMP-driven migration by green tea polyphenol (-)-epigallocatechin-3-gallate in glioblastoma cells. Biochim Biophys Acta 2002; 1542:209-220.
17. Dell'Aica I, Dona M, Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin- 3-gallate directly inhibits MT1-MMP activity, leading to accumulation of nonactivated MMP-2 at the cell surface. Lab Invest 2002; 82:1685-1693.
18. Tachibana H, Koga K, Fujimura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 2004; 11:380-381.
19. Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett 2005; 223:1-10.
20. Freitas VM, Scheremeta B, Hoffman MP, Jaeger RG. Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line. Oral Oncol 2004; 40:483-489.
21. Huwiler A, Akool el-S, Aschrafi A, Hamada FM, Pfeilschifter J, Eberhardt W. ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J Biol Chem 2003; 278:51758-51769.
22. Iyer V, Pumiglia K, DiPersio CM. Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005; 118:1185-1195.
23. Akool el-S, Kleinert H, Hamada FM, Abdelwahab MH, Forstermann U, Pfeilschifter J, et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003; 23:4901-4916.
24. Garde S, Shukeir N, Arakelian A, Chen G, Morin C, Forté A, et al. Inhibition of angiogenesis and MMP-9 production by a synthetic peptide (PCK3145) in a syngeneic model of rat prostate cancer results in decreased tumor growth and skeletal metastasis in vitro and in vivo. [abstract] In: Proc Amer Assoc Cancer Res 2005; 46: 5835 A.
25. Menard S, Tagliabue E, Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 1998; 52:137-1345.
26. Carbone A, Gloghini A, Colombatti A, Castronovo V, Menard S. Expression of the monomeric 67-kd laminin-binding protein in human lymphomas as defined by MLuC5 monoclonal antibody and paraffin section immunohistochemistry. Hum Pathol 1995; 26:541-546.
27. Waltregny D, de Leval L, Coppens L, Youssef E, de Leval J, Castronovo V. Detection of the 67-kD laminin receptor in prostate cancer biopsies as a predictor of recurrence after radical prostatectomy. Eur Urol 2001; 40:495-503.
28. Montuori N, Selleri C, Risitano AM, Raiola AM, Ragno P, Del Vecchio L, et al. Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. Clin Cancer Res 1999; 5:1465-1472.